Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE:532321

₹1095.25 20.65 (1.92%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

1071.00

Today’s High

1115.00

52W low

567.80

52W High

1172.50

Open Price

1080.90

Prev. Close

1045.0000

Volume

2723118.00

Value

2982494989.50

Fundamentals

Market Cap Cr

110207.80

Price to Earnings

28.10

Price to Book Value

5.00

Dividend Yield

0.50

PE to Growth

0.30

Op Revenue TTM Cr

19547.40

Net Profit TTM Cr

3923.30

Cash From Operating Activity Cr

3227.90

Return on Equity %

20.03

EMA & SMA

Bullish Moving Averages

16

Bearish Moving Averages

0

5Day EMA

1071.2

10Day EMA

1072.2

12Day EMA

1072

20Day EMA

1067.7

26Day EMA

1062.7

50Day EMA

1036.8

100Day EMA

972

200Day EMA

861.1

5Day SMA

1067.7

10Day SMA

1073.8

20Day SMA

1071.9

30Day SMA

1066

50Day SMA

1034.6

100Day SMA

987.8

150Day SMA

888.2

200Day SMA

817.7

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

02 Jul, 2024

52.7

Week

62.1

Month

57.9

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

1071.20

PIVOT

First Resistance

1083.40

Second Resistance

1092.20

Third Resistance

1104.40

First Support

1062.40

Second Support

1050.20

Third Support

1041.40

Relative Strength Index

53.76

Money Flow Index

51.46

MACD

9.29

MACD Signal

13.17

Average True Range

30.73

Average Directional Index

14.83

Rate of Change (21)

7.44

Rate of Change (125)

55.92

Commodity Channel Index

-0.3

Williams %R

-60.2

BETA

1 Month

0.62

3 Month

0.82

1 Year

0.52

3 Year

0.16

PRICE CHANGE ANALYSIS

↑ 2.19%

1 Week

Low

High

1050.05

1115

↑ 9.51%

1 Month

Low

High

933.8

1115

↑ 10.3%

3 Months

Low

High

913.2

1172.5

↑ 53.77%

6 Months

Low

High

686

1172.5

↑ 87.85%

1 Year

Low

High

567.75

1172.5

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 3693.50 2478.10 2693.80 3038.10 2830.50 2223.20 2508.00 2032.60 2073.00 1856.20 2078.30
Operating Expenses Qtr 1763.20 1672.20 1509.90 1814.70 1806.80 1628.30 1719.80 1436.60 1561.70 1471.70 1524.60
Operating Profit Qtr 1569.20 699.10 649.40 1141.00 772.50 458.60 679.00 544.30 457.60 358.60 484.30
EBIDT Qtr Cr 1921.70 805.90 1183.90 1223.40 819.90 594.90 788.20 596.00 511.30 384.50 234.40
Depreciation Qtr 130.60 127.70 124.90 121.20 119.90 121.60 124.00 123.10 122.80 120.00 119.20
Net Profit Qtr 1405.20 450.40 805.00 780.90 490.70 255.90 451.10 331.50 246.90 197.00 14.10
Basic EPS Qtr 13.89 4.45 7.96 7.71 4.85 2.53 4.45 3.24 2.41 1.92 0.14
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 11903.50 9280.00 8160.60 7869.30 7196.80
Operating Expenses Annual Cr 6760.00 6277.20 6063.80 5471.30 4924.30
Operating Profit Annual 4058.70 2454.40 1918.10 2308.70 1423.10
Operating Profit Margin Annual % 34.10 26.45 23.50 29.34 19.77
Total Expenses Annual Cr 7655.10 7044.00 6677.40 5993.30 5587.10
EBIDT Annual Cr 5143.50 3002.80 2096.80 2398.00 2272.50
EBIDT Annual margin % 43.21 32.36 25.69 30.47 31.58
Depreciation 504.40 488.60 478.70 451.10 428.90
PAT Before ExtraOrdinary Items Annual Cr 3441.50 1529.20 857.90 1476.20 1353.60
Net Profit Annual 3441.50 1529.20 857.90 1476.20 1412.90
Basic EPS Annual 34.01 15.06 8.38 14.42 13.80
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 15716.50 13639.40 13240.50 12744.50 11260.20
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 5826.90 4134.10 471.60 898.10 1842.00
Total Current Liabilities Annual Cr 2541.40 2790.10 4027.90 4821.00 3449.30
Total Capital Plus Liabilities Annual Cr 24084.80 20563.60 17740.00 18463.60 16551.50
Fixed Assets Annual 5003.30 4923.40 4719.90 4682.50 4661.60
Total Non Current Assets Annual 16149.00 13405.40 10902.60 12431.90 11758.80
Total Current Assets Annual 7935.80 7158.20 6837.40 6031.70 4792.70
Total Assets Annual 24084.80 20563.60 17740.00 18463.60 16551.50
Contingent Liabilities plus Commitments Annual Cr - 752.40 2233.10 2009.30 4090.90
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 1999.10 1078.20 1310.70 2225.30 1180.60
Cash from Investing Activity Annual -1830.60 -1959.70 768.20 -2713.80 55.00
Cash from Financing Annual Activity -300.80 827.00 -1709.80 257.20 -966.70
Net Cash Flow Annual - -54.50 369.10 -231.30 268.90
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 156.23 134.78 129.30 124.46 109.96
ROE Annual % 21.89 11.21 6.47 11.58 12.54
ROCE Annual % 21.53 14.14 11.80 14.27 14.07
Total Debt to Total Equity Annual 0.39 0.35 0.20 0.31 0.26
EBDIT Annual Margin % 47.54 34.39 26.26 30.82 35.80
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 5690.20 4542.90 4422.80 5175.60 5048.40 4400.80 4179.10 4138.60 3942.90 3715.80 3838.10
Operating Expenses Qtr 3903.30 3402.80 3222.70 3634.30 3755.00 3406.30 3319.40 3239.70 3146.10 2902.50 2924.00
Operating Profit Qtr 1630.50 1102.40 1146.10 1505.30 1255.60 956.00 815.30 833.00 717.70 752.50 860.80
EBIDT Qtr Cr 1790.10 1161.90 1199.10 1526.10 689.90 994.90 865.20 887.70 781.80 813.30 3314.50
Depreciation Qtr 205.30 194.80 184.20 179.80 178.60 181.60 181.80 180.70 185.40 183.20 184.80
Net Profit Qtr 1246.10 789.60 800.70 1086.90 296.60 622.90 522.50 518.30 397.40 500.40 3002.30
Basic EPS Qtr 11.69 7.80 7.91 10.74 2.93 6.15 5.15 5.06 3.88 4.89 29.32
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 19831.50 17424.00 15489.90 14449.10 14367.00
Operating Expenses Annual Cr 14163.10 13377.50 11924.50 11016.40 11469.70
Operating Profit Annual 5384.30 3859.90 3340.70 3387.10 2783.40
Operating Profit Margin Annual % 27.15 22.15 21.57 23.44 19.37
Total Expenses Annual Cr 15008.40 14230.10 12764.50 11844.80 12508.00
EBIDT Annual Cr 5668.40 4046.50 3565.40 3432.70 2897.30
EBIDT Annual margin % 28.58 23.22 23.02 23.76 20.17
Depreciation 764.10 722.70 713.00 669.60 696.50
PAT Before ExtraOrdinary Items Annual Cr 3831.40 2001.90 2326.40 2205.60 1175.60
Net Profit Annual 3972.80 1960.30 4487.30 2133.60 1176.60
Basic EPS Annual 38.14 19.30 43.83 20.84 11.49
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 19829.50 17515.80 16999.60 12992.30 10375.70
Minority Interest Liability Annual Cr 2272.10 2172.50 2054.20 1937.30 1334.70
Total Non Current Liabilities Annual Cr 1837.30 537.40 902.20 1093.80 3706.80
Total Current Liabilities Annual Cr 5341.90 5530.70 7839.40 7861.30 8269.40
Total Capital Plus Liabilities Annual Cr 29280.80 25756.40 27795.40 23884.70 23686.60
Fixed Assets Annual 9525.80 7917.20 7549.80 7569.50 7580.50
Total Non Current Assets Annual 17779.40 15740.00 15534.00 15168.70 14971.20
Total Current Assets Annual 11501.40 10016.40 12261.40 8716.00 8715.40
Total Assets Annual 29280.80 25756.40 27795.40 23884.70 23686.60
Contingent Liabilities plus Commitments Annual Cr - 1274.90 1210.70 1295.50 1053.70
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 3227.90 2688.80 2104.10 3293.90 2931.50
Cash from Investing Activity Annual -1475.20 1171.20 1154.40 -724.60 -1012.30
Cash from Financing Annual Activity -1804.40 -4400.40 -868.30 -2547.70 -1528.20
Net Cash Flow Annual - -540.40 2390.20 21.60 391.00
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 219.70 194.55 186.07 145.80 114.36
ROE Annual % 20.03 11.19 26.39 16.42 11.33
ROCE Annual % 20.48 16.43 14.29 17.24 14.27
Total Debt to Total Equity Annual 0.04 0.07 0.25 0.35 0.68
EBDIT Annual Margin % 28.99 23.47 23.35 23.83 20.32
Name Holding Percent Holding Id Pledged % Locked %
Kotak Flexicap Fund 2.3 74207961 - -
Icici Prudential Bluechip Fund 1.15 74207962 - -
Name Holding Percent Holding Id Pledged % Locked %
Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) 74.97 74207956 0 0
Name Holding Percent Holding Id
Kotak Flexicap Fund 2.3 74207961
Icici Prudential Bluechip Fund 1.15 74207962
Llife Insurance Corporation of India 4.43 74207964
Name Holding Percent Holding Id
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Jul 26, 2024 3 FINAL Jul 26, 2024 Equity Share
Jul 28, 2023 6 FINAL Jul 28, 2023 Equity Share
Jul 28, 2022 2.5 FINAL Jul 29, 2022 Equity Share
Jul 28, 2021 3.5 FINAL - Equity Share
Mar 23, 2020 3.5 INTERIM Mar 24, 2020 Equity Share
Jul 25, 2019 3.5 FINAL - Equity Share
Jul 31, 2018 3.5 FINAL - Equity Share
Mar 16, 2017 3.2 INTERIM Mar 17, 2017 Equity Share
Mar 17, 2016 3.2 INTERIM Mar 18, 2016 Equity Share
Jul 30, 2015 12 FINAL - Equity Share
Jul 17, 2014 9 FINAL - Equity Share
Jun 11, 2013 7.5 INTERIM Jun 12, 2013 Equity Share
Jul 26, 2012 7.5 FINAL - Equity Share
Jul 07, 2011 6.25 FINAL - Equity Share
Jul 15, 2010 5 FINAL - Equity Share
Jul 16, 2009 4.5 FINAL - Equity Share
Jul 10, 2008 4.5 FINAL - Equity Share
Jul 12, 2007 4 FINAL - Equity Share
Jul 13, 2006 6 FINAL - Equity Share
Jul 14, 2005 6 FINAL - Equity Share
Jul 14, 2004 6 FINAL - Equity Share
Sep 24, 2003 3.5 FINAL - Equity Share
Sep 11, 2002 - FINAL - Equity Share
Jun 18, 2001 - FINAL - Equity Share
Ex-Date Split Ratio Record Date
Oct 06, 2015 5:1 -
Ex-Date Purpose Notes
May 17, 2024 Audited Results & Final Dividend -
Feb 09, 2024 Quarterly Results & Buy Back of shares -
Nov 07, 2023 Quarterly Results -
Aug 11, 2023 Quarterly Results -
May 18, 2023 Audited Results & Final Dividend -
Feb 03, 2023 Quarterly Results -
Nov 11, 2022 Quarterly Results -
Aug 10, 2022 Quarterly Results -
May 20, 2022 Audited Results, Dividend & Buy Back -
Feb 03, 2022 Quarterly Results -
Oct 29, 2021 Quarterly Results -
Aug 11, 2021 Quarterly Results -
May 27, 2021 Audited Results & Final Dividend -
Feb 05, 2021 Quarterly Results -
Nov 02, 2020 Quarterly Results -
Aug 05, 2020 Quarterly Results -
Jun 19, 2020 Audited Results -
Mar 16, 2020 Interim Dividend -
Feb 05, 2020 Quarterly Results -
Nov 13, 2019 Quarterly Results -
Aug 09, 2019 Quarterly Results -
May 29, 2019 Audited Results & Final Dividend -
Feb 07, 2019 Quarterly Results -
Nov 03, 2018 Quarterly Results -
Aug 13, 2018 Quarterly Results -
May 25, 2018 Audited Results, Dividend & Others -
Feb 08, 2018 Quarterly Results -
Nov 14, 2017 Quarterly Results -
Aug 11, 2017 Quarterly Results -
Jun 26, 2017 Others To raise funds by issue of Equity Shares / Convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR, subject to approval of the shareholders.
May 27, 2017 Audited Results -
Mar 07, 2017 Interim Dividend -
Jan 31, 2017 Quarterly Results -
Nov 17, 2016 Scheme of Arrangement -
Oct 26, 2016 Quarterly Results -
Aug 03, 2016 Quarterly Results -
May 13, 2016 Audited Results & Others To raise funds by issue of Equity Shares / convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR for an aggregate amount upto Rs.10,000 Crores,
Mar 08, 2016 Interim Dividend -
Feb 05, 2016 Quarterly Results -
Oct 22, 2015 Quarterly Results -
Aug 12, 2015 Quarterly Results Approved the sub-division (split) of one equity share of the Company having a face value of Rs.5/- into five equity-shares of face of Rs.1/- each.
May 15, 2015 Audited Results & Dividend To delist Equity Shares of the Company from Ahmedabad Stock Exchange Limited (ASE), in view of non-trading of Equity Shares of the Company on ASE since last so many years.
Feb 10, 2015 Quarterly Results -
Nov 06, 2014 Quarterly Results -
Jul 30, 2014 Quarterly Results -
May 16, 2014 Audited Results & Dividend -
Feb 07, 2014 Quarterly Results -
Oct 31, 2013 Quarterly Results -
Aug 30, 2013 Audited merged accounts To consider and approve the audited merged accounts for the financial year ended on March 31, 2013.
Aug 07, 2013 Quarterly Results -
May 30, 2013 Audited Results & Interim Dividend -
Apr 22, 2013 Scheme of Amalgamation -
Feb 08, 2013 Quarterly Results -
Nov 07, 2012 Quarterly Results -
Aug 06, 2012 Quarterly Results -
May 10, 2012 Audited Results & Dividend -
Feb 07, 2012 Quarterly Results -
Nov 10, 2011 Quarterly Results -
Jul 19, 2011 Quarterly Results -
May 06, 2011 Audited Results & Dividend -
Jan 18, 2011 Quarterly Results & Others The Board will elect the Chairman of the Investors' Grievance Committee.
Oct 19, 2010 Quarterly Results -
Jul 27, 2010 Quarterly Results -
Apr 29, 2010 Audited Results & Dividend -
Feb 25, 2010 Increase the Authorised Capital & Bonus To increase the Authorised Share Capital of the Company from Rs. 700/- Millions to Rs. 1100/- Millions & to issue of Bonus Equity Shares in the ratio 1:2 of Rs. 5/- each fully paid-up Equity Shares.
Jan 25, 2010 Quarterly Results -
Oct 27, 2009 Quarterly Results -
Jul 27, 2009 Quarterly Results -
Apr 28, 2009 Audited Results & Dividend -
Jan 27, 2009 Quarterly Results -
Oct 22, 2008 Quarterly Results -
Jul 29, 2008 Quarterly Results -
Jul 04, 2008 Composite Scheme of Arrangement To approve the "Composite Scheme of Arrangement between Cadila, Carnation and Zydus Hospitals and Medical Research Pvt Ltd".
Jun 17, 2008 To consider Re-structure of CPB To consider options to consolidate / restructure the Consumer Products business of the group, including its listed subsidiary, namely Carnation Nutra-Analogue Foods Ltd.
Apr 29, 2008 Audited Results & Dividend -
Jan 31, 2008 Quarterly Results -
Oct 26, 2007 Quarterly Results -
Jul 31, 2007 Quarterly Results -
Jun 17, 2007 To consider issue f FCCB's inter alia, to consider, to issue Foreign Currency Convertible Bonds (FCCBs) / ADRs / GDRs, etc. subject to approval of shareholders and such other statutory authorities.
Apr 26, 2007 Audited Results & Dividend -
Jan 22, 2007 Quarterly Results -
Oct 31, 2006 Quarterly Results -
Jul 28, 2006 Quarterly Results -
Apr 28, 2006 Bonus issue -
Jan 28, 2006 Quarterly Results -
Oct 22, 2005 Quarterly Results -
Jul 26, 2005 Quarterly Results -
Apr 29, 2005 Accounts & Dividend -
Jan 27, 2005 Quarterly Results -
Oct 25, 2004 Quarterly Results -
Jul 26, 2004 Quarterly Results -
Apr 26, 2004 Dividend & Accounts -
Feb 12, 2004 Amalgamation Amalgamation of Banyan Chemicals Ltd., (the wholly owned subsidiary of the company) with the company.
Jan 20, 2004 Quarterly Results -
Oct 20, 2003 Quarterly Results -
Aug 16, 2003 Accounts & Dividend -
Jul 15, 2003 Quarterly Results -
Apr 30, 2003 Quarterly Results (Revised)
Jan 29, 2003 Quarterly Results -
Oct 24, 2002 Quarterly Results -
Jul 25, 2002 Quarterly Results -
May 15, 2002 Accounts & Dividend -
Mar 08, 2002 Interim Dividend -
Jan 23, 2002 Quarterly Results -
Oct 29, 2001 Quarterly Results -
Jul 23, 2001 Quarterly Results -
May 02, 2001 Accounts -
Jan 22, 2001 Quarterly Results -
Oct 21, 2000 Quarterly Results -
Jul 25, 2000 Quarterly Results -
Apr 24, 2000 Accounts & Dividend -
Ex-Date Bonus Ratio Record Date
Apr 05, 2010 1:2 2010-04-06
Aug 30, 2006 1:1 2006-08-31
Bigul
01 Jul 2024

Zydus Lifesciences Ltd - 532321 - Receipt Of Rectification Order Under Section 154 Of The IT Act

 Receipt of Rectification Order under section 154 of the IT Act
Bigul
28 Jun 2024

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Zydus and Dr. Reddy''s announce licensing agreement for co-marketing of Pertuzumab biosimilar, a critical treatment for breast cancer patients in India.
Bigul
25 Jun 2024

Zydus Lifesciences Ltd - 532321 - Closure of Trading Window

 Closure of trading window
Bigul
20 Jun 2024

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Copy of newspaper publication
Bigul
19 Jun 2024

Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of loss of share certificate under Reg 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Bigul
16 Jun 2024

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Participation in Jefferies Corporate Access Day in Ahmedabad
Bigul
14 Jun 2024

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Zydus receives tentative approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets.
Bigul
04 Jun 2024

Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation for loss of share certificate under Reg 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Bigul
31 May 2024

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Acquisition

 Acquisition of shares
Bigul
28 May 2024

Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of loss of share certificate under Reg 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
See all News

FAQs

The latest market price of Zydus Lifesciences Ltd. on NSE was Rs. 1095.25 as of today.

The opening share price of Zydus Lifesciences Ltd. was Rs. 1080.90 as of today.

The 52-week high share price of Zydus Lifesciences Ltd. was Rs. 1172.50.

The 52 week low share price of Zydus Lifesciences Ltd. was Rs. 567.80.

Zydus Lifesciences Ltd. has a market cap of Rs. 110207.80 crore as of today. Please refer to the Fundamentals section for further details.

The PE ratio of Zydus Lifesciences Ltd. is 0.30. Please refer to the Fundamentals section for further details.

The operating revenue for Zydus Lifesciences Ltd. in the last FY was Rs.  19547.40 crore. Please refer to the Financials section for further details.

The Net Profit for Zydus Lifesciences Ltd. in the last FY was Rs. 3923.30 crore. Please refer to the Financials section for further details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Zydus Lifesciences Ltd. was on 2024-07-26 for Rs. 3 per share. According to today’s share price, the dividend yield of Zydus Lifesciences Ltd. stands at 0.50. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Zydus Lifesciences Ltd. was as of 2010-04-05. The bonus ratio declared in this issue was 1:2. Please refer to the Corporate Actions section for further details.

The latest split issue declared by Zydus Lifesciences Ltd. was as of 2015-10-06. The split ratio declared in this issue was 5:1. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Zydus Lifesciences Ltd..

Close

Let's Open Free Demat Account